Full Product Name
DMPK siRNA (Human)
Product Synonym Names
DM1PK; MDPK; Myotonin-protein kinase; MT-PK; DM-kinase; DMK; DM1 protein kinase; DMPK; Myotonic dystrophy protein kinase
Product Gene Name
DMPK sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q09013
Specificity
DMPK siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human DMPK gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of DMPK sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
DMPK sirna
siRNA to inhibit DMPK expression using RNA interference
Applications Tested/Suitable for DMPK sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for DMPK. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001075029.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001081560.2
[Other Products]
UniProt Primary Accession #
Q09013
[Other Products]
UniProt Secondary Accession #
Q16205; Q6P5Z6; E5KR08[Other Products]
UniProt Related Accession #
Q09013[Other Products]
Molecular Weight
60,790 Da
NCBI Official Full Name
myotonin-protein kinase isoform 3
NCBI Official Synonym Full Names
dystrophia myotonica-protein kinase
NCBI Official Symbol
DMPK??[Similar Products]
NCBI Official Synonym Symbols
DM; DM1; DMK; MDPK; DM1PK; MT-PK
??[Similar Products]
NCBI Protein Information
myotonin-protein kinase
UniProt Protein Name
Myotonin-protein kinase
UniProt Synonym Protein Names
DM-kinase; DMK; DM1 protein kinase; DMPK; Myotonic dystrophy protein kinase
Protein Family
Myotonin-protein kinase
UniProt Gene Name
DMPK??[Similar Products]
UniProt Synonym Gene Names
DM1PK; MDPK; MT-PK; DMK??[Similar Products]
UniProt Entry Name
DMPK_HUMAN
NCBI Summary for DMPK
The protein encoded by this gene is a serine-threonine kinase that is closely related to other kinases that interact with members of the Rho family of small GTPases. Substrates for this enzyme include myogenin, the beta-subunit of the L-type calcium channels, and phospholemman. The 3' untranslated region of this gene contains 5-37 copies of a CTG trinucleotide repeat. Expansion of this unstable motif to 50-5,000 copies causes myotonic dystrophy type I, which increases in severity with increasing repeat element copy number. Repeat expansion is associated with condensation of local chromatin structure that disrupts the expression of genes in this region. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been determined. [provided by RefSeq, Jul 2008]
UniProt Comments for DMPK
DMPK1: Non-receptor serine/threonine protein kinase which is necessary for the maintenance of skeletal muscle structure and function. May play a role in myocyte differentiation and survival by regulating the integrity of the nuclear envelope and the expression of muscle-specific genes. May also phosphorylate PPP1R12A and inhibit the myosin phosphatase activity to regulate myosin phosphorylation. Also critical to the modulation of cardiac contractility and to the maintenance of proper cardiac conduction activity probably through the regulation of cellular calcium homeostasis. Phosphorylates PLN, a regulator of calcium pumps and may regulate sarcoplasmic reticulum calcium uptake in myocytes. May also phosphorylate FXYD1/PLM which is able to induce chloride currents. May also play a role in synaptic plasticity. Defects in DMPK are the cause of dystrophia myotonica type 1 (DM1); also known as Steinert disease. A muscular disorder characterized by myotonia, muscle wasting in the distal extremities, cataract, hypogonadism, defective endocrine functions, male baldness and cardiac arrhythmias. The causative mutation is a CTG expansion in the 3'-UTR of the DMPK gene. A length exceeding 50 CTG repeats is pathogenic, while normal individuals have 5 to 37 repeats. Intermediate alleles with 35-49 triplets are not disease-causing but show instability in intergenerational transmissions. Disease severity varies with the number of repeats: mildly affected persons have 50 to 150 repeats, patients with classic DM have 100 to 1,000 repeats, and those with congenital onset can have more than 2,000 repeats. Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. DMPK subfamily. 12 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral; Mitochondrial; EC 2.7.11.1; Protein kinase, Ser/Thr (non-receptor); Protein kinase, AGC; Kinase, protein; AGC group; DMPK family; GEK subfamily
Chromosomal Location of Human Ortholog: 19q13.3
Cellular Component: nuclear outer membrane; endoplasmic reticulum membrane; nuclear membrane; sarcoplasmic reticulum membrane; plasma membrane; cytosol; integral to mitochondrial outer membrane
Molecular Function: myosin phosphatase regulator activity; protein serine/threonine kinase activity; protein binding; metal ion binding; ATP binding
Biological Process: cellular calcium ion homeostasis; regulation of catalytic activity; protein amino acid phosphorylation; nuclear membrane organization and biogenesis; regulation of heart contraction
Disease: Myotonic Dystrophy 1
Research Articles on DMPK
1. In conclusion, our data suggest that the frequency of DMPK mutation carriers and the prevalence of DM1 in the Korean population might be higher than those reported in other ethnicities. Supporting
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
